Ventana PD-L1 (SP142) Assay

被引：0
|
作者：
McGill, Rachel [1 ]
Michail, Ramez [1 ]
Miller, Brianne [1 ]
Milton, Erica [1 ]
Musyoka, Agnes [1 ]
Musyoka, Rhoda [1 ]
O'Conner, Jada [1 ]
Ogunnaike, Morenike [1 ]
Omeke, Soteria [1 ]
Franklin, Gallop [1 ]
Honeywell, Marlon S. [1 ]
机构：
[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Inst Publ Hlth, Tallahassee, FL 32307 USA
来源：
US PHARMACIST | 2022年 / 47卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：42 / 44
页数：3
相关论文
共 50 条
  • [31] Utilization of Commercial SP142 PD-L1 Testing of Breast Carcinomas at a Large Academic Cancer Center
    Wong, Serena
    Reisenbichler, Emily
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 164 - 165
  • [32] A budget impact analysis of the VENTANA PD-L1 SP142 immunohistochemistry assay versus the Dako PD-L1 IHC 22C3 assay in patients with advanced or metastatic triple-negative breast cancer treated with atezolizumab in combination with nab-paclitaxel
    Scatena, Cristian
    Ravasio, Roberto
    Raimondo, Paola
    Giuliano, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2021, 22 (01)
  • [33] Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
    Ahn, Sung Gwe
    Kim, Seon-Kyu
    Shepherd, Jonathan H.
    Cha, Yoon Jin
    Bae, Soong June
    Kim, Chungyeul
    Jeong, Joon
    Perou, Charles M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) : 165 - 178
  • [34] Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
    He, Jiankun
    Wang, Xinran
    Cai, Lijing
    Jia, Zhanli
    Liu, Chang
    Sun, Xuemei
    Wu, Si
    Ding, Chunyan
    Zhang, Zi
    Liu, Yueping
    DIAGNOSTIC PATHOLOGY, 2023, 18 (01)
  • [35] PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
    Comperat, Eva
    Oszwald, Andre
    Wasinger, Gabriel
    Wacquet, Justine
    Roupret, Morgan
    Cussenot, Olivier
    WORLD JOURNAL OF UROLOGY, 2021, 39 (11) : 4067 - 4071
  • [36] Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples.
    Scott, Marietta
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Barker, Craig
    Scorer, Paul
    Rebelatto, Marlon
    Al-Masri, Hytham
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [37] PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)
    Jing Ma
    Jianhui Li
    Meirui Qian
    Weili Han
    Miaomiao Tian
    Zengshan Li
    Zhe Wang
    Shuixiang He
    Kaichun Wu
    Diagnostic Pathology, 13
  • [38] Digital pathologist training program on the evaluation of PD-L1 expression by VentanaPD-L1 (SP142) in triple negative breast cancer
    Viegas, M.
    Schmitt, D. F.
    Pereira, H.
    Pinto Torres, S.
    Rebelo, A. S.
    Matos, D.
    Dias, A.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S2 - S2
  • [39] Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263 E1L3N).
    Schats, Kelly
    Van Vre, Emily A.
    Schrijvers, Darien
    De Meester, Ingrid
    Kockx, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
    Nielsen, Alma
    Manriquez, Guadalupe
    Hayden, Dorothy
    Lian, Fangru
    Liu, Chunyan
    Patil, Pallavi
    Wang, Peiyi
    Gu, Pengfei
    Schnittker, Karina
    Roland, Bryan
    Quiroz, Michelle
    Newell, Amy Hanlon
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 830 - 831
12345